Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

GOGOX IPO: Overseas Business Maintains Growth but China Biz Under Pressure Due to Competition

2022 High Conviction – Medlive: Key Beneficiary of Digital Healthcare Marketing in China

Shanghai Bio-Heart IPO: Strong Product Candidates but For Those Willing to Wait

Clover Biopharmaceuticals IPO: Forecasts and Valuation

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lepu-biopharma-co-ltd" target="_blank" data-smartkarma-citation="entities:33231:1" rel="noopener">Lepu Biopharma (LBP HK)</a> is a biopharmaceutical company focusing on oncology therapeutics. The company has filed for an IPO to list in the Hong Kong Stock Exchange.</li>
<li>The company has the leading ADC drug candidate pipeline in China, in terms of the number of clinical-stage ADC drug candidates.</li>
<li>However, Lepu Biopharma is yet to generate any revenues with no monetisation timeline mentioned, despite the company’s strong product portfolio.</li>
</ul>



Lepu Biopharma (LBP HK) is a biopharmaceutical company focusing on oncology therapeutics. The company has filed for an IPO to list in the Hong Kong Stock Exchange.
The company has the leading ADC drug candidate pipeline in China, in terms of the number of clinical-stage ADC drug candidates.
However, Lepu Biopharma is yet to generate any revenues with no monetisation timeline mentioned, despite the company’s strong product portfolio.


Lepu Biopharma IPO: No Monetisation Timeline in Sight